Benefits of gut microbiota reconstitution by beta 1,3-1,6 glucans in subjects with autism spectrum disorder and other neurodegenerative diseases

Manuscript Number: 

22-0388R2

Author(s): 
Samuel J.K. Abraham, Vidyasagar Devaprasad Dedeepiya, Nobunao Ikewaki, Masaru Iwasaki, Senthilkumar Preethy, Kadalraja Raghavan, Rajappa Senthilkumar, Ramesh Shankar Kandaswamy, Tohru Sonoda, Naoki Yamamoto

Disclosures

Samuel J.K. Abraham

  • Equity:
    Author Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; also a board member in both the companies.
    Patents/Royalties
    Author Samuel Abraham is an inventor to several patents of relevance to the beta glucans described in the study.

Vidyasagar Devaprasad Dedeepiya

  • Nothing to Disclose

Nobunao Ikewaki

  • Nothing to Disclose

Masaru Iwasaki

  • Nothing to Disclose

Senthilkumar Preethy

  • Nothing to Disclose

Kadalraja Raghavan

  • Nothing to Disclose

Rajappa Senthilkumar

  • Nothing to Disclose

Ramesh Shankar Kandaswamy

  • Nothing to Disclose

Tohru Sonoda

  • Nothing to Disclose

Naoki Yamamoto

  • Nothing to Disclose